CRISPR unlocks a new way to defeat resistant lung cancer

Researchers at ChristianaCare's Gene Editing Institute used CRISPR technology to turn off the NRF2 gene in lung cancer cells, successfully restoring their sensitivity to chemotherapy drugs like carboplatin and paclitaxel. The breakthrough shows that editing just 20% to 40% of tumor cells can slow cancer growth and enhance treatment response, offering hope for overcoming drug resistance across multiple cancer types.